Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial

Date

09 Oct 2016

Session

Genitourinary tumours, prostate

Presenters

Felix Feng

Citation

Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372

Authors

F.Y. Feng1, S. Daignault-Newton2, A. Jendrisak3, Y. Wang3, S. Greene3, A. Rodriguez3, J. Lee3, L. Dugan3, J. Siddiqui4, J. Louw3, C. Johnson3, P. Twardowski5, C. Albany6, M. Stein7, W.M. Stadler8, L. Kunju4, A.M. Chinnaiyan4, M. Landers3, R. Dittamore9, M. Hussain10

Author affiliations

  • 1 Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, 94143-0511 - San Francisco/US
  • 2 Biostatistics, University of Michigan, 48109-5010 - Ann Arbor/US
  • 3 Translational Research, Epic Sciences, Inc, 92121 - San Diego/US
  • 4 Michigan Center For Translational Pathology, University of Michigan, 48109-5010 - Ann Arbor/US
  • 5 Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 6 Medical Oncology, Indiana University Simon Cancer Center, 46202 - Indianapolis/US
  • 7 Division Of Medical Oncology, The Cancer Institute of New Jersey, New Brunswick/US
  • 8 Medical Oncology, The University of Chicago Medical Centre, 60637 - Chicago/US
  • 9 Translational Research, Epic Sciences Inc., 92121 - San Diego/US
  • 10 Medical Oncology, University of Michigan, Ann Arbor/US
More

Resources

Background

PARP inhibitors (PARPi) have efficacy in mCRPC harboring homologous recombination DNA repair deficiencies (HRD), but there is no non-invasive assay to predict PARPi response. Previous work characterizing single CTCs from mCRPC pts has identified subclonal populations of CTCs with unique phenotypes and somatic genomic instability consistent with HRD and resulting in worse outcomes following abiraterone (A) treatment. NCI 9012 evaluated A alone with or without the PARPi veliparib (V) in mCRPC pts. We now determine if the addition of V to A improves pts response and its association with phenotypic HRD CTC signature.

Methods

84 baseline & 58 on-therapy blood samples from unique pts randomized to V + A vs A arms on NCI 9012 (baseline n = 44 vs 40, follow-up n = 34 vs 24, respectively) were analyzed with the Epic Sciences CTC platform. CTC analysis included digital pathology of 20 discrete phenotypic cell features inclusive of AR, CK, size and shape. 3323 single CTCs were characterized and analyzed for HRD+ signature utilizing the previously developed classifier. A subset of CTCs (n= 309) from 40 samples (30 patients) were individually sequenced and analyzed for genomic instability and resistant mechanism.

Results

The HRD+ CTC phenotype was confirmed to have high cell level concordance (79%) vs. genomic scar (NGS). In baseline samples, HRD+ CTC phenotype occurred in 39% (V + A) and 30% (A), and had a higher ORR (>50% PSA drop) in the V + A vs the A cohort (88% vs 42%, p = 0.01). No significant difference observed in V + A vs the A cohort (62% vs 78%, p = 0.24) for HRD- patients. For patients with both baseline and short term follow up (

Conclusions

Prevalence of a unique morphologically derived CTC subtype predicts genomic HRD and sensitivity to V + A but not A alone. Novel markers of resistance have identified patients not suitable for PARPi despite HRD+. Further validation is ongoing.

Clinical trial identification

NCI 9012 trial

Legal entity responsible for the study

Felix Feng

Funding

NCI

Disclosure

F.Y. Feng: Advisory boards: Medivation, Astellas. President and co-Founder of PFS Genomics, a molecular diagnostics company focused on personalizing radiotherapy for breast cancer patients.

A. Jendrisak, Y. Wang, S. Greene, A. Rodriguez, J. Lee, L. Dugan, J. Louw, C. Johnson, M. Landers, R. Dittamore: Epic Sciences employee. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings